HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Launched by HRYZ BIOTECH CO. · Mar 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called HRYZ-T101 TCR-T cell therapy for patients with advanced solid tumors that are positive for HPV-18, which is a type of human papillomavirus linked to certain cancers like cervical and head and neck cancers. The goal is to find out how safe and effective this treatment is for people who have already tried other treatments without success. The study is currently looking for participants aged 18 to 70 who have confirmed HPV-18 infection and specific health conditions, such as having measurable cancer lesions and a good overall health status.

If you or someone you know is eligible and decides to participate, you will receive injections of the HRYZ-T101 TCR-T cells and will be monitored closely for safety and effectiveness. Participants will need to agree to use effective birth control during the study and for a while after treatment. It’s important to note that those with certain health issues, recent surgeries, or specific infections may not be able to join the trial. This study aims to provide new hope for patients facing limited treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient must be willing to sign the informed consent form.
• • 2. Age ≥18 years and ≤70 years.
• • 3. Histologically-confirmed advanced metastatic or recurrent solid tumors with confirmed HPV18 infection and HLA-DRB1\*09:01 allele.
• • 4. Subjects who have failed at least first-line treatment in the past and lack effective treatment options.
• • 5. ECOG performance status of 0-1.
• • 6. Estimated life expectancy ≥ 3 months.
• • 7. Patients must have at least one measurable lesion defined by RECIST 1.1.
• • 8. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 6 months after receiving HRYZ-T101 cell transfusion treatment.
• 9. Patients with any organ dysfunction as defined below:
• • 1) Leukocytes≥3.0 x 10\^9/L; 2) absolute neutrophil count ≤1.5 x 10\^9/L; 3) blood platelets ≥75 x 10\^9/L; 4) hemoglobin≥90g/L; 5) Serum albumin ≥ 3.0g/dL; 6) total bilirubin≤1.5×ULN; ALT/AST≤2.5×ULN; 7) Creatinine clearance ≥50mL/min; 8) INR≤1.5×ULN; APTT≤1.5×ULN; 9) LVEF≥50%; 10) SpO2≥92%.
• Exclusion Criteria:
• • 1. Organ transplanters and allogeneic cell transplanters.
• • 2. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
• • 3. Those who have undergone major surgery within 4 weeks before enrollment, and those who have received conventional chemotherapy, large-area radiotherapy, targeted therapy, endocrine therapy, immunotherapy or biological therapy, and Chinese herbal medicine and other anti-tumor treatment.
• • 4. Have received live attenuated vaccine within 4 weeks before enrollment.
• • 5. Subjects with clinical cardiac symptoms or diseases that cannot be well controlled.
• • 6. The subject has active infection or fever more than 38.5 degrees of unknown cause during screening and before cell transfusion.
• • 7. Subjects have any active autoimmune disease or history of autoimmune disease.
• • 8. Subjects with other malignant tumors.
• • 9. Patients with central nervous system metastasis.
• • 10. Active, uncontrolled bacterial or fungal infection requiring systemic treatment.
• • 11. Known HIV or syphilis infection, and/or active hepatitis B virus or hepatitis C virus infection.
• • 12. It is planned to use immunosuppressive agents, or systemic corticosteroids, immunomodulators.
• • 13. Have received any investigational drug within 4 weeks before enrollment, or have participated in another clinical study at the same time.
• • 14. Pregnant or lactating subjects, or those who are unwilling to contraception during the test.
• • 15. Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure.
• • 16. Other serious organic diseases and mental disorders.
• • 17. Have received any gene therapy products before.
• • 18. According to the judgment of the researcher, those who are not suitable for the group, such as poor compliance.